Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“Multiple ADCs have outperformed chemo for treating metastatic breast cancer. Yet, their most transformative impact is expected in the curative setting.
DESTINY-Breast11 (announced to be positive!) will report at ESMO25, and so much more is coming. We review the rapidly evolving field of ADCs to cure early breast cancer in our latest NPJ Breast review, led by Pooja Patel.”
Title: Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions
Authors: Pooja Patel, Antonio Giordano, Sara Giordano, Ilana Schlam, Sara M. Tolaney, Paolo Tarantino
Read the Full Article.
